Chronic morphine treatment suppresses CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen.
Exposure to opioid drugs (e.g., morphine) in vivo has been shown to suppress natural killer cell activity. However, the effects of in vivo exposure to opioids on cytotoxic T lymphocyte (CTL) activity has not been investigated. The administration of morphine (50.0 mg/kg, sc) to alloimmunized mice for 11 days resulted in a significant decrease in peritoneal and splenic CTL activity. Moreover, the intracellular content of serine esterases and esterase release by CD8+ effector cells from chronic morphine-treated mice was reduced compared to that of effector cells from vehicle-treated controls. In addition, the CD8+ cAMP response to alloantigen was diminished compared to CD(8+)-enriched cells from vehicle-treated animals. However, conjugate formation between effector and target and subsequent killing of target by effector cells did not reveal significant differences between vehicle- and chronic morphine-treated animals. Serum corticosterone and dehydroepiandrosterone levels were significantly lower in the chronic morphine-treated animals while proopiomelanocortin gene expression (exon 3) in splenic lymphocytes did not correlate with morphine-mediated suppression of CTL activity. These results indicate that CTL activity is sensitive to chronic morphine exposure, implicating opioids as important cofactors during viral infections in suppressing cell-mediated immunity.
Carpenter
G W
GW
Department of Microbiology, Louisiana State University Medical Center, New Orleans 70112-1393.
Garza
H H
HH
Gebhardt
B M
BM
Carr
D J
DJ
D000818:Animals; D001483:Base Sequence; D003345:Corticosterone / Q000097:blood; D000242:Cyclic AMP / Q000096:biosynthesis*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D003687:Dehydroepiandrosterone / Q000097:blood; D004198:Disease Susceptibility / Q000276:immunology; D004950:Esterases / Q000032:analysis; D005091:Exons; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006561:Herpes Simplex / Q000276:immunology; D007114:Immunization; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007519:Isoantigens / Q000276:immunology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009020:Morphine / Q000494:pharmacology*; D015213:Neuroimmunomodulation; D016133:Polymerase Chain Reaction; D011333:Pro-Opiomelanocortin / Q000096:biosynthesis / Q000235:genetics; D013564:Sympathetic Nervous System / Q000503:physiopathology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000201:enzymology
D007166:Immunosuppressive Agents; D007519:Isoantigens; D003687:Dehydroepiandrosterone; D011333:Pro-Opiomelanocortin; D009020:Morphine; D000242:Cyclic AMP; D004950:Esterases; C022635:serine esterase; D003345:Corticosterone